KDL Medical released its 2026 interim report, showing first-half net profit attributable to the parent of 112 million yuan, down 10.2% year on year. Operating revenue was 1.09 billion yuan, down 3.2%; non-GAAP net profit attributable to the parent was 110 million yuan, down 10.5%; and net operating cash flow was 116 million yuan, up 57.1%. Second-quarter operating revenue was 552 million yuan, down 4.3%, with net profit attributable to the parent of 58.18 million yuan, down 9.6%. The company said market demand for injection and puncture medical consumables is steadily rising, and the market is expected to expand to 35.61 billion US dollars by 2033.
Shanghai Kindly Entrp Dvlp GrpFirst-half net profit fell 10.2% and revenue declined 3.2%.